Viking Therapeutics Inc (VKTX) Q1 2020 earnings call dated Apr. 30, 2020 Corporate Participants: Stephanie Diaz -- Manager, Investor Relations Brian Lian -- President and Chief
Viking Therapeutics Inc.
-(VKTX)
XNAS:VKTX
Viking Therapeutics Inc (NASDAQ: VKTX) Q4 2019 Earnings Call Transcript
Viking Therapeutics Inc (NASDAQ: VKTX) Q4 2019 Earnings Conference Call February 26, 2020 Corporate Participants: Stephanie C. Diaz -- President and Chief Executive Officer Brian
Viking Therapeutics (VKTX): Q3 2019 Earnings Snapshot
-- Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected. -- Net
Viking Therapeutics Q4 loss widens on higher expenses but beats estimates
Viking Therapeutics (VKTX) Wednesday posted a wider net loss for the fourth quarter of 2018, owing to a sharp increase in research
Earnings: Trevena slips on wider-than-expected Q4 loss
Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market trading. Helped
Viking Therapeutics earnings preview: All eyes on NASH
Viking Therapeutics (VKTX) is scheduled to report fourth-quarter 2018 financial results on March 13, Wednesday, after the regular trading hours. The market
Intercept stock surges on positive data from liver fibrosis drug study
Intercept Pharmaceuticals (ICPT) had surged about 25% in the pre-market session on Tuesday after the biopharma company announced positive topline results from
Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump
Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results and a
Why Ligand Pharma, Viking Therapeutics tumbled yesterday, but is gaining today
Shares of Ligand Pharmaceuticals (LGND) took a beating on Wednesday after a bearish report by Citron Research led by short-seller Andrew Left